Autopsy report · NCT04210037
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Registered 8 months before it started.
- Ran for about 1 year 9 months before it stopped.
- 28 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Ascentage Pharma Group Inc.
- Sponsor type
- Industry
- Conditions
- Small Cell Lung Cancer
- Interventions
- APG-1252; Paclitaxel
- Participants
- 28
- Sites
- 8
- Countries
- Australia, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.